Weekly News Recap #Phispers
FDA issues warning letter to Chinese supplier of semaglutide; approves AstraZeneca’s new treatment for hypertension
In Phispers this week, the US Food and Drug Administration (FDA) approved AstraZeneca’s first-in-class treatment for hype...
Impressions : 2228
India’s Sun Pharma acquires Organon for about US$ 11.75 bn; Lilly to buy Ajax Therapeutics for up to US$ 2.3 bn
In Phispers this week, Indian drugmaker Sun Pharmaceutical acquired Jersey-based Organon in an all-cash deal valued at about US...
Impressions : 1883
Neurocrine buys Soleno for US$ 2.9 bn; Novo says Wegovy pill outperforms Lilly’s Foundayo in cross-trial comparison
In Phispers this week, Neurocrine Biosciences announced the
acquisition of rare-disease drugmaker Soleno Therapeutics for US$ ...
Impressions : 1505
Lilly to invest US$ 3 bn in China to boost supply of new obesity drug; Servier acquires Day One Biopharma for US$ 2.5 bn
In Phispers this week, Eli Lilly announced its plans to invest US$
3 billion in China over the next decade in order to build p...
Impressions : 2552
Gilead buys Arcellx for US$ 7.8 billion; FDA approves Vanda’s antipsychotic pill for bipolar disorder, schizophrenia
In this week’s news, Gilead Sciences has entered into an agreement to acquire its cancer therapy partner Arcellx for US$ ...
Impressions : 945
FDA refuses to review Moderna’s mRNA-based flu vaccine application; Lilly buys Orna for up to US$ 2.4 billion
The US Food and Drug Administration (FDA) has said it will not review Moderna’s application for its experimental influenz...
Impressions : 1827
Lilly expects 25% growth, Novo sees its sales drop in 2026; Amgen turns down FDA request to withdraw rare disease drug
In this week’s Phispers, we bring you the split story of two GLP-1 drugmakers — Eli Lilly and Novo Nordisk. While L...
Impressions : 2850
US exits WHO; Moderna to stop investing in new late-stage vaccine trials due to increased opposition to immunizations
Public health suffered several setbacks over the last week. First,
the United States formally exited the World Health Organiza...
Impressions : 1992
AbbVie inks US$ 5.6 bn oncology deal with China’s RemeGen; Astra buys Modella AI to speed up cancer drug research
This week’s Phispers is packed with news from the ongoing JP Morgan Healthcare Conference (JPM26). Notably, AbbVie said i...
Impressions : 1611
Lilly becomes first pharma to hit US$ 1 tn valuation; FDA clears Padcev-Keytruda combo for bladder cancer
In Phispers this week, Eli Lilly became the first pharmaceutical company to reach a market valuation of US$ 1 trillion, driven ...
Impressions : 1816
Innovent, Takeda ink up to US$ 11.4 bn oncology deal; FDA clears Novo’s Rybelsus to reduce heart risk in diabetics
In this week’s Phispers, China’s Innovent Biologics signed one of the largest cross-border biotech deals in Asia. U...
Impressions : 1558
Novo targets MASH with up to US$ 5.2bn Akero buy; BMS acquires cell therapy developer Orbital for US$ 1.5 bn
In this week’s Phispers, Novo Nordisk and Bristol Myers Squibb (BMS) struck multi-billion-dollar acquisitions to expand t...
Impressions : 1212
Novartis inks US$ 5.7 bn licensing deal with Monte Rosa for immune-related diseases; GSK, Lilly pledge more investments in US
In this week’s news, drugmakers continued to invest heavily in the US in order to avoid tariffs. GSK said it will invest ...
Impressions : 1341
Advent to sell generic unit to PE firm GTCR for US$ 4.8 billion; Novo shapes up for obesity race by cutting 9,000 jobs
In this week’s news, Advent International has agreed to sell the Czech generic drugmaker Zentiva to private equity firm G...
Impressions : 1211
FDA grants accelerated approval to Wegovy for treating MASH; Lilly, Superluminal ink US$1.3 bn AI deal to treat obesity
This week’s Phispers brings you updates on key drug approvals. The US Food and Drug Administration (FDA) has granted acce...
Impressions : 2011
FDA grants accelerated nod to Boehringer’s lung cancer med; reinstates ousted CBER chief Vinay Prasad
The US Food and Drug Administration (FDA) has granted an accelerated approval to Boehringer Ingelheim’s Hernexeos (zonger...
Impressions : 1864
Trump says pharma tariffs may touch 250% in 18 months; FDA okays Jazz Pharma’s rare brain tumor drug
The US Food and Drug Administration (FDA) has granted an accelerated approval to Jazz Pharmaceuticals’ Modeyso, a drug th...
Impressions : 1160
Astra to invest US$ 50 bn in US to avoid tariffs; Dr. Reddy’s to launch generic Wegovy in 87 countries next year
AstraZeneca and Biogen are the latest drugmakers to
announce investments in the US to avoid import tariffs. AstraZeneca is
in...
Impressions : 1923
Royalty Pharma inks US$ 2 bn cancer drug deal with Revolution; Astra-Daiichi’s Datroway wins US approval for lung cancer
In news this week, Royalty Pharma committed up to US$ 2 billion to Revolution Medicines for their promising pancreatic and lung...
Impressions : 3193
RFK Jr fires all 17 members of CDC’s vaccine committee; Merck’s oral cholesterol drug meets goals in late-stage trials
This week, US Health and Human Services (HHS) Secretary
Robert F. Kennedy Jr. dismissed all 17 members of the US Centers for D...
Impressions : 1567
BMS partners BioNTech in US$ 11 bn cancer drug deal; Sanofi to acquire Blueprint Medicines for US$ 9.5 bn
The pharmaceutical sector saw several significant deals with major players expanding their portfolios. Bristol Myers Squibb (BM...
Impressions : 811
Pfizer inks US$ 6 bn oncology deal with China’s 3SBio; BioNTech to invest US$ 1.3 bn in UK for new R&D, AI centers
In news this week, Pfizer announced a US$ 6 billion licensing agreement with China’s 3SBio, securing global rights to a p...
Impressions : 879
Trump signs ‘most favored nation’ executive order to slash drug costs; Sanofi, Takeda pledge mega investments in US
The US President Donald Trump’s dramatic intervention in pharmaceutical pricing took centerstage as the White House unvei...
Impressions : 1021
BMS to invest US$ 40 bn to boost US manufacturing, R&D; 19 states sue Trump admin for gutting health agencies
US President Donald Trump’s tariff threats appear to be working, as Bristol Myers Squibb became the latest drugmaker to a...
Impressions : 2004
Roche announces US$ 50 bn investment in US to avoid tariffs; Regeneron signs US$ 3 bn onshoring deal with Fujifilm
After Eli Lilly, Johnson & Johnson and Novartis, Roche has announced plans to manufacture in the US to avoid tariffs. The Swiss...
Impressions : 1460
Novartis to invest US$ 23 bn in US to avoid import tariffs; Pfizer halts development of GLP-1 weight-loss pill
After Eli Lilly and
Johnson & Johnson, Novartis has become the latest big pharma to announce
mega investments in the US. The ...
Impressions : 1195
Mallinckrodt, Endo merge in US$ 6.7 bn deal; Astra buys cell therapy developer EsoBiotec; Pfizer sells entire stake in Haleon
In Phispers this week, two drugmakers emerging from bankruptcy — Mallinckrodt and Endo — are merging in order to le...
Impressions : 1328
Roche buys rights to Zealand’s obesity med in US$ 5.3 bn deal; Merck wins Gardasil lawsuit, bolsters vaccine manufacturing
In news this week, Roche has acquired rights to develop and commercialize Zealand Pharma’s experimental obesity drug petr...
Impressions : 1509
- Privacy policy
- Terms and conditions
- Disclaimers
-
- Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.